| |
|
|
|
Health Network Communications, London
2010/3/26
Day One - Wednesday 24 March 2010
| 08.00 | Registration & coffee
| 08.45 | Opening remarks from the chair
| 09.00 | Keynote address: valuing the benefits of pharmaceuticals
• How should we value an individual’s benefits? • How should we weigh the benefits to different people and conditions? | | |
| 09.25 | Policy challenges in market access for pharmaceuticals in Europe
• Key policy developments over the last 12 months • Cost containment strategies and impact on market access • New deals and pricing models | | |
| 09.50 | Speed networking
 Fun, high speed breaks for making new contacts and exchanging business cards.
| 10.20 | Morning tea
| 10.45 | Innovation and the new PPRS
• The innovation package in the PPRS • Patient access schemes/flexible pricing in the PPRS • Innovation post high quality care for all • The OLS blueprint and the innovation pass | | | Matt Harpur , Senior Policy Manager for Pricing and Cost Effectiveness, Department of Health , United Kingdom
| 11.10 | Strategic medicines management and prescribing in Wales - view from AWMSG
• Prescribing and medicines management • Medicines management achievements • Making the vision a reality | | |
| 11.35 | NICE – latest developments in HTA policy in England and Wales
• Highlights of the updated technology appraisal process • The PPRS and processes for submitting Patient Access schemes • A new evaluation pathway for medical technologies | | |
| 12.00 | Health Technology Assessment in Ireland
• Health policy drivers in Ireland • Pricing and reimbursement framework • HTA practice and the assessment of pharmaceuticals | | |
| 12.25 | Lunch
| 13.25 | France: latest developments in pricing and reimbursement policy | | |
| 13.50 | Germany: latest developments in pricing and reimbursement policy
• Federal Joint Committee – introduction to the operative framework • Cost-effectiveness analyses and ceiling prices in Germany – the way forward • Co-signing procedure for special pharmaceuticals – first experiences | | |
| 14.15 | IQWiG Update
• Examining the new evaluation system, how it is different and what it hopes to achieve • Understanding the main decision making criteria of the institute • Recent results of IQWiQ evaluations | | |
| 14.45 | Delivering quality and value in pharmaceutical products | | |
| 15.15 | Afternoon tea
| 16.30 | Canada: latest developments in pricing and reimbursement policy
• Healthcare system in Canada • History of the Pharmaceutical Provisions of the Patent Act • PMPRB mandate • Price regulatory regime • Regulations and guidelines • Pharmaceutical trends | | |
| 16.45 | USA: healthcare reform and government reimbursement
• US health reform update • Industry’s role in the debate • Changes to government reimbursement programs • Predictions on impact to pharmaceutical pricing & market access
| 17.00 | Canada: the changing pricing and reimbursement environment
• Impact and implications of the new PMPRB price guidelines • HTA and CADTH / Common Drug Review / Joint Oncology Drug Review • Risk sharing, listing agreements and the evolving provincial reimbursement schemes • Parallel trade: decline of Canadian internet pharmacy, is US importation still feasible? • Outlook for P&R in Canada | | |
| 17.30 | Closing remarks from the chair
| 17.45 | Drinks reception
The evening drinks reception is an opportunity to relax and network over drinks with conference attendees.
| 19.00 | End of day one
| |
Day Two - Thursday 25 March 2010
| 08.30 | Registration and coffee
| 09.00 | Opening remarks from the chair | | |
| | NEW THINKING IN PRICING AND REIMBURSEMENT | | | 09.15 | A global view on pharma pricing & market access
• Global payer segmentation • Recent developments and trends • Implications for evolving P&MA evidence needs • Risk sharing: an opinion | | |
| 09.45 | Industry viewpoint on risk sharing agreements
• What are the principles behind the various schemes? • When is risk sharing appropriate and when is it not? • What role should industry play? | | | Anne-Toni Rodgers, Director, Government Affairs and Public Policy - Europe, Baxter World Trade SA, Belgium
| 10.15 | Is risk sharing the way forward?
• Why are companies offering risk-sharing agreements? • Who gains? And what do they gain? • What is the future of risk sharing? Is this a new business relationship? | | | Mr Jim Furniss, Director, Global Market Access, Bridgehead International Ltd, United Kingdom
| 10.45 | Morning tea
| 11.15 | Value communication: the next 10 years
• Downward cost pressure and the role of value communication in healthcare • The problems faced in communicating value • The future of value communication | | |
| 11.45 | The rise of a common EU assessment on drugs
• Collaboration until now • Recent developments • EMEA, MEDEV, EUnetHTA | | |
| 12.15 | Improving access to medicines
• How will new market access models improve availability of new treatments to patients? • What has been done? • What more is to be achieved? • What role should stakeholders play? | | | Confirmed:
Anne-Toni Rodgers, Director, Government Affairs and Public Policy - Europe, Baxter World Trade SA, Belgium
| 13.00 | Lunch
| | MARKET UPDATE EUROPE | | | 13.55 | Opening remarks from the chair | | | Mr Jim Furniss, Director, Global Market Access, Bridgehead International Ltd, United Kingdom
| 14.00 | Italy: latest changes in reimbursement and pricing policy legislation
• Access to medicines in Italy under the NHS • Criteria for pricing and reimbursement • Governance of pharmaceutical expenditure • Experiences with risk sharing and conditional reimbursement | | |
| 14.30 | Norway: latest changes in reimbursement and pricing policy legislation
• Price level in Norway compared to 9 other West-European countries • Price regulation of pharmaceuticals: on patent-segment and segment with generic substitution • Reimbursement system | | | Helga Festøy, Head of Section, Norwegian Mediines Agency, Norway
| 15.00 | Afternoon tea
| | MARKET UPDATE – ASIA | | | 16.00 | Japan pricing and reimbursement system: current and future panoramas and its implications for global pricing strategies
• Pricing and reimbursement system in Japan • P&R data needs and implications for drug development programs • P&R evolution and consequences for the global pricing strategy | | | Susana Murteira, Head of Pricing & Reimbursement Division, Lundbeck SAS, France
| 16.30 | China: latest developments in pricing and reimbursement policy
• Country overview • Economy • Demography • Healthcare system • Pharmaceutical market • Chinese medical security system • Chinese pharmaceutical pricing policy • Opportunities and challenges | | | Dr Ziyan Wang, Manager, Health Economics, Johnson & Johnson, Belgium
| 17.00 | Closing remarks from the chair
| 17.15 | End of conference
| | |
|
|
|
|
|
|
|
|
Organized by:
|
|
Health Network Communications |
|
|
Invited Speakers:
|
|
Head of the Research Department of Standardization, Licensing and Accreditation, Moscow Medical Academy | |
Chief Executive, HIQA, Ireland | |
Chair in Economics, Imperial College, United Kingdom | |
Managing Director, Medaxial Group, United Kingdom | |
Head of Section, Norwegian Mediines Agency, Norway | |
Head of Osmed Unit, AIFA, Italy | |
Director, Global Market Access, Bridgehead International Ltd, United Kingdom | |
Senior Policy Manager for Pricing and Cost Effectiveness, Department of Health , United Kingdom | |
Manager, ZS Associates, United States | |
Dr Peter Kolominsky-Rabas, Former Head of Department, IQWiG, Germany | |
Health Technology Evaluation Director, NICE, United Kingdom | |
Head of Pharmaceuticals, GBA, Germany | |
Head of Pricing & Reimbursement Division, Lundbeck SAS, France | |
President, PDCI Market Access, Canada | |
Vice President Corporate Relations, GlaxoSmithKline, United Kingdom | |
Member if the Board, HAS, France | |
Director, Government Affairs and Public Policy - Europe, Baxter World Trade SA, Belgium | |
Prof Philip Routledge, OBE, Chairman, AWMSG, United Kingdom | |
Head of Reimbursement, CVZ | |
Dr Regina Skavron, Programme Officer, Pharmaceuticals Division, GBA, Germany | |
Dr Martin van der Graaff, Secretary, Reimbursement Committee, CVZ | |
Manager, Health Economics, Johnson & Johnson, Belgium | |
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
ASAP
|
|
|
|
|
|
|
|
Registration:
|
|
Basic packages Currency: GBP (£ Pounds)Gold pass - all 4 days £2,385 2 day conference plus x1 workshop £1,800 2 day conferece £1,215 To register contact Katie Barden on +44 (0) 20 7608 7085 |
|
|
E-mail:
|
|
kbarden@healthnetworkcommunications.com
|
|
|
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking
|
|
|
|
|
|
|
|
|
|
